WO2009081789A1 - スルホニル置換六員環誘導体 - Google Patents
スルホニル置換六員環誘導体 Download PDFInfo
- Publication number
- WO2009081789A1 WO2009081789A1 PCT/JP2008/072811 JP2008072811W WO2009081789A1 WO 2009081789 A1 WO2009081789 A1 WO 2009081789A1 JP 2008072811 W JP2008072811 W JP 2008072811W WO 2009081789 A1 WO2009081789 A1 WO 2009081789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- compound
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention is useful in the field of medicine. More specifically, the sulfonyl-substituted six-membered ring derivative of the present invention is a long chain fatty acid elongase (Long chain fatty acyl elongase; hereinafter abbreviated as LCE) inhibitor, which is used for various cardiovascular diseases and nervous systems. It is useful as a therapeutic agent or herbicide for diseases, metabolic diseases, reproductive system diseases, gastrointestinal diseases, neoplasms, infectious diseases and the like.
- LCE long chain fatty acid elongase
- Obesity is a condition in which neutral fat accumulates in adipocytes due to the persistence of excessive intake energy compared to energy consumption, resulting in a marked increase in body weight compared to standard weight (Itagaki). Eiji, “STEP Metabolism / Endocrine”, Kaiba Shobo, 1st Edition, 1998, p. 105). It is known that excessive accumulated fat causes insulin resistance, diabetes, hypertension, hyperlipidemia, etc., and the risk of developing arteriosclerosis is greatly increased by combining these factors. Such symptoms are called metabolic syndrome.
- hypertriglyceridemia or obesity is, for example, pancreatitis, liver dysfunction, cancer such as breast cancer / uterine cancer / ovarian cancer / colon cancer / prostate cancer, menstrual abnormality, arthritis, gout, cholecystitis, gastroesophageal reflux, obesity It is known to increase the risk of hypoventilation syndrome (Pickwick syndrome), sleep apnea syndrome, and the like.
- diabetes is likely to cause, for example, angina pectoris, heart failure, stroke, lameness, retinopathy, decreased visual acuity, renal failure, neuropathy, skin ulcer, infection, etc. [The Merck Manual of Medical Information, Home 2nd Edition, Merck & Co, 2003].
- LCE is an enzyme that exists in the endoplasmic reticulum in the cell, and is an enzyme that catalyzes the rate-limiting condensation step in an enzyme group that catalyzes the carbon chain elongation reaction of fatty acids having 12 or more carbon chains.
- many of the fatty acids newly synthesized in vivo have a chain length of 16-18 carbons.
- These long chain fatty acids are over 90% of the total fatty acids present in the cell. They are an important constituent of the cell membrane and a major component of adipose tissue, the largest energy storage organ in animals. It is the liver that has the highest rate of new fatty acid synthesis, and this synthesis converts excess glucose in the body into fatty acids.
- Glycolysis converts glucose to pyruvate, which is converted to citrate by mitochondria and transported to the cytosol.
- Cytosolic ATP citrate lyase produces acetyl CoA, a precursor of fatty acids and cholesterol.
- Acetyl CoA is carboxylated by acetyl CoA carboxylase (ACC) to form malonyl CoA.
- the multifunctional enzyme fatty acid synthase (FAS) uses malonyl CoA, acetyl CoA, and NADPH to elongate fatty acids by two carbons.
- the main end product of FAS in rodents is palmitoyl CoA with 16 carbon chains, which is extended by two carbons by LCE [Journal of Biological Chemistry (J.
- Patent Document 1 shows a direct relationship between LCE and obesity.
- LCE mouse FACE
- LCE is also present in protozoa and nematodes, and is known to be involved in cell growth.
- trypanosomiasis which is the cause of African trypanosomiasis (popular name: African sleeping sickness)
- long-chain fatty acids are synthesized by the fatty acid elongation pathway including LCE, and inhibition of intracellular fatty acid elongation reaction contributes to the growth of trypanosomes.
- the compound of the present invention is a derivative having a sulfonyl in a saturated six-membered ring, but a compound in which aryl or heteroaryl is bonded to the 3-position of a substituted sulfonyl saturated six-membered ring via an amide bond or a urea bond is conventionally known. It is not done. J. et al. Lipid Res. 43 (6), 911-920 (2002) Cell, 126: 691-699 (2006)
- An object of the present invention is to provide a novel compound having an LCE inhibitory action.
- Z is selected from the group consisting of the following formulas (II-1), (II-2) and (II-3);
- n and n are each 0, 1 or 2
- Y represents CR 3 or N, provided that when Y represents N, in (II-2) or (II-3), n represents 0 or 2
- R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, aryl or heteroaryl is hydroxy, cyano, carboxyl, sulfo, halogen, C 1-6 alkyl, halo C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, amino (said amino, C 1-6 alkyl, 1 or 2 substituted by an aryl or heteroaryl Carbamoyl (the carbamoyl may be substituted with 1 to 2 alkyls by C 1-6 alkyl, aryl or heteroaryl), sulfanyl (the sulfanyl is C 1-6 alky
- the present invention provides (2) a long-chain fatty acid elongation enzyme (LCE) inhibitor comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, (3) a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, (4) There is also provided a preventive or therapeutic agent for diabetes, obesity or non-alcoholic fatty liver, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- LCE long-chain fatty acid elongation enzyme
- LCE LCE inhibitory action
- various diseases involving LCE such as hypertension, angina pectoris, heart failure, myocardial infarction, stroke, lameness, diabetic nephropathy, diabetic retinopathy, visual acuity Decrease, electrolyte abnormality, arteriosclerosis and other cardiovascular diseases such as bulimia, diabetic neuropathy, etc.
- Central nervous system diseases such as metabolic syndrome, obesity, diabetes, insulin resistance, hyperlipidemia, high cholesterol Metabolic disorders such as dyslipidemia, hypertriglyceridemia, dyslipidemia, nonalcoholic fatty liver, abnormal hormone secretion, gout, fatty liver, etc.
- reproductive system diseases such as menstrual disorders, sexual dysfunction, liver dysfunction , Pancreatitis, cholecystitis, gastrointestinal tract disease such as gastroesophageal reflux, obesity hypoventilation syndrome (Pickwick syndrome), respiratory apnea syndrome such as sleep apnea syndrome, infection by bacteria, fungi, parasites Disease, malignant neoplasms, arthritis, preventive agents such as inflammatory diseases such as skin ulcers, therapeutic agents, or are useful as herbicides.
- reproductive system diseases such as menstrual disorders, sexual dysfunction, liver dysfunction , Pancreatitis, cholecystitis, gastrointestinal tract disease such as gastroesophageal reflux, obesity hypoventilation syndrome (Pickwick syndrome), respiratory apnea syndrome such as sleep apnea syndrome, infection by bacteria, fungi, parasites Disease, malignant neoplasms, arthritis, preventive agents such as inflammatory diseases such as skin ulcers, therapeutic agents, or are useful as herbicides.
- Halogen means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- C 1-6 alkyl means linear or branched alkyl having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl. , Isopentyl, hexyl, isohexyl and the like.
- Halo C 1-6 alkyl substitutable or differently one, preferably refers to C 1-6 alkyl substituted with 1 to 3 same or different aforementioned halogen atoms, such as fluoro And methyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, chloromethyl, 2-chloroethyl, 1,2-dichloroethyl, bromomethyl, iodomethyl and the like.
- C 3-8 cycloalkyl means cycloalkyl having 3 to 8 carbon atoms, and examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- alkyl is optionally halogen, cyano, nitro, oxo, —OR 5 , —R 5 , —COR 5 , —CO 2 R 5 , —NR 6 R 7.
- C 1-6 alkoxy means straight or branched alkoxy having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, isobutoxy, tert-butoxy, Examples include pentyloxy, isopentyloxy, hexyloxy, isohexyloxy and the like.
- Halo C 1-6 alkoxy substitutable or differently one, preferably means C 1-6 alkoxy substituted with 1 to 3 same or different aforementioned halogen atoms, such as fluoro Examples include methoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 1,2-difluoroethoxy, chloromethoxy, 2-chloroethoxy, 1,2-dichloroethoxy, bromomethoxy, iodomethoxy and the like.
- C 1-6 alkoxycarbonyl is a group in which C 1-6 alkoxy is bonded to carbonyl, and examples thereof include methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl and the like.
- C 1-6 alkoxycarbonylamino is a group in which one hydrogen atom of an amino group (—NH 2 ) is substituted with C 1-6 alkoxycarbonyl, such as methoxycarbonylamino, ethoxycarbonylamino, n- And propyloxycarbonylamino.
- C 1-6 alkylcarbonyl is a group in which C 1-6 alkyl is bonded to carbonyl, and examples thereof include acetyl, propionyl, isobutyryl, valeryl, isovaleryl, pivaloyl and the like.
- C 1-6 alkylcarbonylamino is a group in which one hydrogen atom of an amino group is substituted with C 1-6 alkylcarbonyl.
- acetylamino, propionylamino, isobutyrylamino, valerylamino, isovale Rylamino, pivaloylamino and the like can be mentioned.
- C 1-6 alkylsulfonyl is a group in which C 1-6 alkyl is bonded to a sulfonyl group, and examples thereof include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl and the like.
- C 1-6 alkylsulfonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with C 1-6 alkylsulfonyl.
- methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, etc. Can be mentioned.
- C 1-6 alkylsulfinyl is a group in which C 1-6 alkyl is bonded to a sulfinyl group, and examples thereof include methylsulfinyl, ethylsulfinyl, n-propylsulfinyl and the like.
- aryl examples include phenyl, naphthyl and the like.
- Heteroaryl is a 5-membered or 6-membered monocyclic ring containing 1 or 2 or more, preferably 1 to 3 heteroatoms, which are the same or different from the group consisting of oxygen atom, nitrogen atom and sulfur atom.
- a fused cyclic heteroaryl in which the monocyclic heteroaryl is fused with the aryl, or the same or different monocyclic heteroaryl is fused with each other, such as pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl , Thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2 , 4-Triazini 1,3,5-triazinyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzo
- aryl or “heteroaryl” is, for example, hydroxy, cyano, halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, haloC 1-6 Alkoxy, C 3-8 cycloalkoxy, amino, C 1-6 alkylamino, diC 1-6 alkylamino, halo C 1-6 alkylamino, dihalo C 1-6 alkylamino, C 3-8 cycloalkylamino, DiC 3-8 cycloalkylamino, carbamoyl, C 1-6 alkylcarbamoyl, diC 1-6 alkylcarbamoyl, haloC 1-6 alkylcarbamoyl, dihaloC 1-6 alkylcarbamoyl, C 3-8 cycloalkylcarbamoyl, di C 3-8 cycloalkylcarbamoyl, thiol
- Arylcarbonyl is a group in which the aryl is bonded to carbonyl.
- Heteroarylcarbonyl is a group in which the heteroaryl is bonded to carbonyl.
- Arylcarbonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with the arylcarbonyl.
- Heteroarylcarbonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with the heteroarylcarbonyl.
- Aryloxy is a group in which the aryl is bonded to an oxygen atom.
- Heteroaryloxy is a group in which the heteroaryl is bonded to an oxygen atom.
- Aryloxycarbonyl is a group in which the aryloxy is bonded to carbonyl.
- Heteroaryloxycarbonyl is a group in which the heteroaryloxy is bonded to carbonyl.
- Aryloxycarbonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with the aryloxycarbonyl.
- Heteroaryloxycarbonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with the heteroaryloxycarbonyl.
- Arylsulfinyl is a group in which the aryl is bonded to sulfinyl.
- Heteroarylsulfinyl is a group in which the heteroaryl is bonded to flufinyl.
- Arylsulfonyl is a group in which the aryl is bonded to sulfonyl.
- Heteroarylsulfonyl is a group in which the heteroaryl is bonded to sulfonyl.
- Arylsulfonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with the arylsulfonyl.
- Heteroarylsulfonylamino is a group in which one of the hydrogen atoms of the amino group is substituted with the heteroarylsulfonyl.
- aralkyl means a group in which the aryl and C 1-6 alkyl are bonded, and examples thereof include benzyl, 1-phenylethyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylmethyl and the like.
- Heteroaralkyl means a group in which the heteroaryl is bonded to the C 1-6 alkyl.
- Alkyloxy means a group in which the aralkyl is bonded to an oxygen atom.
- Heteroaralkyloxy means a group in which the heteroaralkyl is bonded to an oxygen atom.
- Heterocyclyl means monocyclic containing 4 to 10 atoms containing 1, 2 or 3 heteroatoms selected from saturated, partially saturated or unsaturated nitrogen, oxygen and sulfur
- a bicyclic ring wherein the ring nitrogen atom may be substituted by a group selected from C 1-6 alkyl, amino-C 1-6 alkyl, aryl, aryl-C 1-6 alkyl and acyl
- the “salt” of the compound of the present invention means a conventional pharmaceutically acceptable salt, for example, when it has a carboxyl group, a base addition salt at the carboxyl group or an amino group or a basic heterocyclic group And acid addition salts in the basic heterocyclic group.
- the base addition salt examples include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; such as trimethylamine salt, triethylamine salt, dicyclohexylamine salt and ethanolamine.
- organic amine salts such as salts, diethanolamine salts, triethanolamine salts, procaine salts, and N, N′-dibenzylethylenediamine salts.
- the acid addition salt examples include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate and perchlorate; for example, maleate, fumarate, tartrate, citrate, ascorbate, Organic acid salts such as trifluoroacetates; for example, sulfonates such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate, and the like.
- inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate and perchlorate
- maleate, fumarate, tartrate, citrate, ascorbate Organic acid salts such as trifluoroacetates
- sulfonates such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate, and the like.
- Any substitutable position means a hydrogen atom that can be chemically substituted on a carbon atom, nitrogen atom, oxygen atom and / or sulfur atom, and is chemically stable as a result of the substitution. Represents the position to give the compound.
- the compounds of the present invention may have stereoisomers or tautomers such as optical isomers, diastereoisomers and geometric isomers depending on the mode of the substituents or the salt form.
- the compound also includes all these stereoisomers, tautomers and mixtures thereof.
- the present invention includes various crystals, amorphous, salts, hydrates and solvates of the compounds according to the present invention.
- prodrugs of the compounds of the invention are also within the scope of the invention.
- such prodrugs are functional derivatives of the compounds of the present invention that can be readily converted into the required compounds in vivo. Therefore, in the method for treating various diseases according to the present invention, the term “administration” refers not only to the administration of the specified compound but also to the administration of a compound that is converted into the specified compound in vivo after being administered to a patient. including. Conventional means for selection and production of suitable prodrug derivatives are described, for example, in “Design of Prodrugs” ed. H. Bundgaard, Elsevier, 1985, etc. Metabolites of these compounds include active compounds produced by placing the compounds of the present invention in a biological environment and are within the scope of the present invention.
- R 1 represents C 1-6 alkyl, C 3-8 cycloalkyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, aryl or heteroaryl is hydroxy, cyano, carboxyl, sulfo, halogen, C 1-6 alkyl, halo C 1-6 alkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, amino (said amino, C 1-6 alkyl, 1 or 2 substituted by an aryl or heteroaryl Carbamoyl (the carbamoyl may be substituted with 1 to 2 alkyls by C 1-6 alkyl, aryl or heteroaryl), sulfanyl (the sulfanyl is C 1-6 alkyl, aryl or hetero aryl may be monosubstituted with), C 1-6 alkylsulfinyl, a Rusurufiniru, heteroaryl arylsulf
- R 1 is preferably C 1-6 alkyl, C 3-8 cycloalkyl, aryl or heteroaryl, wherein the group is halogen, C 1-6 alkyl, halo C 1-6 alkyl and C 1-6 alkoxy The thing which may be substituted by the substituent selected from the group which consists of is illustrated.
- R 1 examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3- Fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methoxyphenyl, 3- Methoxyphenyl, 4-methoxyphenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, 2-thieny
- R 2 represents phenyl or heteroaryl, which is hydroxy, cyano, carboxyl, sulfo, halogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-8 cycloalkyl, C 1 -6 alkoxy, halo C 1-6 alkoxy, amino (said amino, C 1-6 alkyl, may be 1 or 2 substituted by an aryl or heteroaryl), carbamoyl (said carbamoyl, C 1-6 alkyl , Aryl or heteroaryl may be substituted by 1 to 2), sulfanyl (the sulfanyl may be monosubstituted by C 1-6 alkyl, aryl or heteroaryl), C 1-6 alkylsulfinyl, arylsulfinyl, heteroaryl sulfinyl, C 1-6 alkylsulfamoyl , Arylsulfonyl, heteroarylsulfonyl,
- R 2 is preferably phenyl or heteroaryl, which is halogen, C 1-6 alkyl, halo C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, aryl And those optionally substituted with a substituent selected from the group consisting of aralkyl and aralkyloxy.
- R 2 include phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-isopropoxyphenyl, 3-isopropoxy Phenyl, 4-isopropoxyphenyl, 2-isobutyroxyphenyl, 3-isobutyroxyphenyl, 4-isobutyroxyphenyl, 2-cyclopropyloxyphenyl, 3-cyclopropyloxyphenyl, 4-cyclopropyloxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2- Feno Xylphenyl, 3-phenoxyphenyl, 4-phenoxyphenyl,
- Y represents CR 3 or N, preferably CR 3 is recommended.
- R 3 represents a hydrogen atom, C 1-6 alkyl, aralkyl, aryl or heteroaryl, wherein the alkyl, aralkyl, aryl or heteroaryl is halogen, C 1-6 alkyl, halo C 1-6 alkyl, C 1 It may be substituted with a substituent selected from the group consisting of -6 alkoxy and halo C 1-6 alkoxy.
- R 3 examples include a hydrogen atom, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, isopentyl, phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, and pyrimidine.
- -2-yl, benzyl and the like are exemplified, and preferably a hydrogen atom, methyl, ethyl, propyl, isopropyl, phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl or benzyl is recommended.
- R 4 has the same meaning as R 3 .
- R 4 is preferably a hydrogen atom.
- Z is selected from the group consisting of the following formulas (II-1), (II-2) and (II-3).
- n 0, 1 or 2 respectively.
- Y is N
- n is 0 or 2.
- M is preferably 0 or 1.
- N is preferably 0 or 1.
- n is preferably 0.
- the formula (II-1) or the formula (II-2) is particularly preferable, and more preferably (II-1) is recommended.
- M 1 , M 2 , M 3 and M 4 each independently represent a hydrogen atom or C 1-6 alkyl optionally substituted with halogen, or M 1 represents M 2 , M 3 Or together with M 4 to form —CH 2 — or —CH 2 —CH 2 —, or M 4 together with M 2 to form —CH 2 — or —CH 2 —CH 2 -Form.
- M 1 , M 2 , M 3 and M 4 are each independently a hydrogen atom, methyl, ethyl, n-propyl, n-butyl, chloromethyl, fluoromethyl, trifluoromethyl and the like. Or M 1 together with M 2 , M 3 or M 4 to form —CH 2 — or —CH 2 —CH 2 —, or M 4 together with M 2 — CH 2 — or —CH 2 —CH 2 — is formed.
- M 1 , M 2 , M 3 and M 4 1) M 1 together with M 2 forms —CH 2 — or —CH 2 —CH 2 —, and M 3 and M 4 are each independently a hydrogen atom or optionally halogen.
- M 1 together with M 3 forms —CH 2 — or —CH 2 —CH 2 —, and M 2 and M 4 are each independently a hydrogen atom or optionally halogen.
- M 1 together with M 4 forms —CH 2 — or —CH 2 —CH 2 —
- M 2 and M 3 are each independently a hydrogen atom or optionally halogen.
- M 1 , M 2 , M 3 and M 4 are hydrogen atoms
- M 1 , M 2 , M 3 and M 4 are hydrogen atoms
- M 1 , M 2 , M 3 and M 4 are C 1-6 alkyl optionally substituted with halogen, and the other is a hydrogen atom
- M 1 , M 2 , M 3 and M 4 are all preferably hydrogen atoms.
- the compound according to the present invention can be produced , for example, by the following production method or the method shown in Examples. However, the method for producing the compound according to the present invention is not limited to these examples.
- Manufacturing method 1 The compound represented by the formula (I-1) can be prepared by the following method.
- Process 1 Compound 1 is subjected to an amidation reaction with Compound 2 in an organic solvent to obtain Compound 3.
- the amidation method can be performed by a conventionally known method.
- the compound 1 and the compound 2 are reacted in the presence of a condensing agent, or the carboxylic acid moiety of the compound 1 is activated by a conventionally known method. And then amidating the derivative with compound 2 (both methods are described in “Peptide Synthesis Fundamentals and Experiments” (Nobuo Izumiya et al., Maruzen Co., Ltd., 1983)). See
- the following method is exemplified as the reaction using a condensing agent.
- compound 1 and compound 2 are condensed in a reaction solvent using a condensing agent to obtain compound 3.
- the amount of compound 2 used is 1 to 3 moles per mole of compound 1.
- Condensation agents include dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide, O-(-7-azabenzotriazol-1-yl) -1,1,3,3-tetra-methyl Examples thereof include uronium hexafluorophosphate (hereinafter referred to as “HATU”), and the amount used thereof is 1 to 3 moles per mole of compound 1.
- HATU uronium hexafluorophosphate
- hydroxybenzotriazole (hereinafter referred to as “HOBT”) or the like may be added to the reaction system for the purpose of promoting the reaction.
- HOBT hydroxybenzotriazole
- Examples of the amount of HOBT used include 1 to 3 moles per mole of Compound 1.
- reaction solvent examples include tetrahydrofuran (hereinafter referred to as “THF”), 1,4-dioxane, N, N-dimethylformamide (hereinafter referred to as “DMF”), dimethyl sulfoxide (hereinafter referred to as “DMSO”), dichloromethane, chloroform. Or the mixed solvent is illustrated.
- reaction temperature 0 to 100 ° C. is exemplified, preferably 0 to 50 ° C. is recommended, and the reaction is usually completed in 1 to 24 hours.
- Compound 3 obtained by the above method can be easily isolated and purified by ordinary separation means.
- Examples of such means include solvent extraction, recrystallization, column chromatography, preparative thin layer chromatography and the like (the same applies in the following methods).
- the compound 1 is exemplified by 3-oxocyclohexanecarboxylic acid
- the compound 2 is exemplified by 3-isopropoxy-1H-pyrazol-5-amine, 4-isopropoxyaniline and the like.
- Process 2 Compound 3 is reduced to a compound 4 by a known method in a reaction solvent.
- the reduction method is not particularly limited, and the ketone moiety may be reduced by a conventionally known method using a reducing agent such as lithium aluminum hydride or sodium borohydride.
- Process 3 Compound 4 is obtained by mesylating compound 4.
- the method of mesylation is not particularly limited, for example, it can be performed by a method combining mesyl chloride as a mesylation reagent and triethylamine as a base.
- Process 4 Compound 5 is reacted with Compound 6 in the presence of a base in a reaction solvent to obtain Compound 7.
- the amount of compound 6 used is 1 to 10 moles per mole of compound 5, and preferably 1 to 5 moles.
- Examples of the base include sodium carbonate, potassium carbonate, cesium carbonate and the like.
- Examples of the amount of the base used include 1 to 10 mol per mol of compound 5, preferably 1 to 5 mol.
- reaction solvent examples include DMF, THF, 1,4-dioxane and the like.
- the reaction temperature is 20 to 130 ° C., preferably 20 to 100 ° C. is recommended, and the reaction is usually completed in 3 to 24 hours.
- potassium iodide may be added to the reaction solution.
- the amount of potassium iodide used is 1 to 10 mol per mol of compound 5, preferably 1 to 5 mol is recommended.
- compound 6 examples include thiophenol, 2-mercaptopyridine, 2-mercaptopyrimidine, 2-mercaptothiazole and the like.
- Process 5 The compound represented by formula (I-1) is obtained by oxidizing compound 7.
- the oxidation method is not particularly limited, for example, m-chloroperbenzoic acid, potassium permanganate or the like can be used.
- reaction is carried out in a solvent such as methylene chloride or chloroform.
- Examples of the amount of m-chloroperbenzoic acid used include 2 to 5 moles with respect to 1 mole of compound 7, and the reaction may be usually performed at room temperature for 1 to 5 hours.
- potassium permanganate when used, it is carried out in a mixed solvent of acetone / water.
- acetic acid may be added to the reaction system.
- Examples of the amount of potassium permanganate used include 2 to 6 mol per 1 mol of compound 7.
- Examples of the amount of acetic acid used include 1 to 10 mol per mol of compound 7.
- the reaction temperature is 20 to 80 ° C, and the reaction is usually completed in 1 to 24 hours.
- the compound represented by the formula (I-1) thus obtained can be easily isolated and purified by ordinary separation means.
- Examples of such means include solvent extraction, recrystallization, column chromatography, preparative thin layer chromatography and the like.
- Manufacturing method 2 is a method for separately synthesizing a compound represented by formula (I-1) using compound 1 ′ as a raw material.
- Step 7 Compound 8 is obtained by mesylating compound 1 ′.
- the mesylation method can be carried out according to Step 3.
- Process 8 Compound 8 is reacted with Compound 6 to give Compound 9. This reaction can be performed according to Step 4.
- Step 9 Compound 10 is obtained by oxidizing compound 9.
- the oxidation method is in accordance with step 5.
- Step 10 Compound 11 is obtained by hydrolyzing the ester of compound 10.
- the method of hydrolysis is not particularly limited, and for example, the hydrolysis can be performed at a temperature from room temperature to the boiling point of the solvent using an aqueous solution of sodium hydroxide or aqueous potassium hydroxide in an organic solvent such as methanol or ethanol.
- Step 11 Compound 11 is reacted with Compound 2 in a reaction solvent to obtain a compound represented by the formula (I-1).
- the reaction method can be performed according to Step 1.
- Manufacturing method 3 is a method for producing a compound represented by formula (I-1a).
- Step 12 Compound 12 is reacted with Compound 6 in a reaction solvent to give Compound 13.
- the reaction method is in accordance with step 4.
- Compound 12 is exemplified by benzyl 3-[(methylsulfonyl) oxy] piperidine-1-carboxylate.
- Step 13 Compound 14 is obtained by oxidizing compound 13.
- the oxidation method is in accordance with step 5.
- Step 14 The amino protecting group of compound 14 is deprotected to give compound 15.
- the deprotection method include Protective Groups in Organic Synthesis, T. et al. W. It can be carried out by the method described in Green (TW Greene, John Wiley & Sons (1981)) or a method analogous thereto.
- the protecting group include tert-butyloxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl and the like.
- the deprotection can be carried out by subjecting compound 14 to a hydrogenation treatment in the presence of palladium carbon in a solvent such as methanol.
- Step 15 Compound 15 is reacted with Compound 16 in an organic solvent to obtain a compound represented by the formula (I-1a).
- the amount of compound 16 used is 1 to 4 moles per mole of compound 15, preferably 1 to 2 moles.
- Examples of the compound 16 include phenyl (4-isopropoxyphenyl) carbamate, phenyl (2-methoxyphenyl) carbamate, and the like.
- reaction solvent examples include chloroform, methylene chloride, THF, 1,4-dioxane and the like.
- reaction temperature 0 to 100 ° C. is exemplified, preferably 0 to 80 ° C. is recommended, and the reaction is usually completed in 1 to 5 hours.
- Manufacturing method 4 is a method for producing a compound represented by formula (I-2) using compound 10 as a raw material.
- Step 16 Reduction of the ester moiety of compound 10 using a reducing agent such as lithium aluminum hydride, sodium borohydride or the like by a conventionally known method yields compound 17.
- a reducing agent such as lithium aluminum hydride, sodium borohydride or the like
- Step 17 Compound 18 and phthalimide are condensed by Mitsunobu reaction to obtain compound 18.
- Examples of the azo compound include dimethyl azodicarboxylate, diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1 ′-(azodicarbonyl) dipiperidide, and the triarylphosphine includes triphenylphosphine, Examples include trilylphosphine, and examples of trialkylphosphine include triethylphosphine and tributylphosphine. Among them, a combination of diisopropyl azodicarboxylate and triphenylphosphine, or a combination of 1,1 '-(azodicarbonyl) dipiperidide and tributylphosphine is recommended.
- Examples of the amount of phthalimide used include 1 mol to 10 mol, preferably 1 mol to 1.5 mol, per 1 mol of compound 17.
- the amount of the azo compound and organophosphorus compound used is, for example, 1 to 3 moles of the azo compound, preferably 1 to 1.5 moles per mole of the compound 17, and preferably 1 mole to phthalimide. On the other hand, 1 to 3 moles of the organophosphorus compound is exemplified, and preferably 1 to 1.5 moles is recommended.
- reaction solvent examples include halogenated carbons such as methylene chloride, chloroform, dichloroethane and carbon tetrachloride; aliphatic hydrocarbons such as n-heptane and n-hexane; aromatic hydrocarbons such as benzene, toluene and xylene; Ethers such as diethyl ether, THF, dioxane, ethylene glycol dimethyl ether; esters such as methyl acetate and ethyl acetate; acetonitrile, N-methylpyrrolidone (hereinafter referred to as “NMP”), DMF, DMSO, or a mixed solvent thereof Is exemplified.
- halogenated carbons such as methylene chloride, chloroform, dichloroethane and carbon tetrachloride
- aliphatic hydrocarbons such as n-heptane and n-hexane
- aromatic hydrocarbons such as benz
- reaction temperature 0 ° C. to 100 ° C. is exemplified, preferably 0 ° C. to 50 ° C. is recommended, and the reaction is usually completed in 2 hours to 24 hours.
- Step 18 Compound 18 is treated with hydrazine in a reaction solvent to give compound 19.
- Examples of the amount of hydrazine used include 1 to 10 mol, preferably 1 to 5 mol per mol of compound 18.
- reaction solvent examples include methanol and ethanol.
- the reaction temperature is 0 to 60 ° C., preferably 0 to 30 ° C.
- the reaction is usually completed in 1 to 24 hours.
- Step 19 Compound 19 is condensed with compound 20 according to step 1 to obtain a compound represented by formula (I-2).
- Examples of the compound 20 include 2-methoxybenzoic acid, 3-methoxybenzoic acid, 4-methoxybenzoic acid, 4-isopropoxybenzoic acid and the like.
- Production method 5 is a method for producing a compound represented by formula (I-3).
- Step 20 Compound 19 is reacted with compound 21 in the presence of a base in a reaction solvent to obtain a compound represented by formula (I-3).
- Examples of the compound 21 include phenyl isocyanate, 4-methoxyphenyl isocyanate and the like, and the amount used thereof is 1 to 4 moles, preferably 1 to 2 moles per mole of the compound 19. .
- Examples of the base include triethylamine, diisopropylethylamine, pyridine and the like, and the amount of the base used is 1 to 5 mol, preferably 1 to 3 mol based on 1 mol of the compound 19.
- reaction solvent examples include pyridine, THF, 1,4-dioxane, methylene chloride, chloroform, DMSO and the like.
- reaction temperature 0 to 100 ° C. is exemplified, preferably 0 to 50 ° C. is recommended, and the reaction is usually completed in 1 to 24 hours.
- amino protecting group examples include aralkyl such as benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl, trityl; C 1-6 alkanoyl such as pivaloyl; eg benzoyl; aryl alkanoyl such as phenylacetyl, phenoxyacetyl; C 1-6 alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, tert-butoxycarbonyl; Aralkyloxycarbonyl such as carbonyl, p-nitrobenzyloxycarbonyl, phenethyloxycarbonyl; for example, trimethylsilyl, tert-butyldimethylsilyl, etc. 1-6 include alkylsilyl etc., especially acetyl, pivaloyl, benzo
- hydroxy protecting group examples include substituted silyl such as trimethylsilyl, tert-butyldimethylsilyl (hereinafter sometimes referred to as “TBDMS”), tert-butyldiphenylsilyl and the like, methoxymethyl, 2-methoxyethoxymethyl and the like.
- examples include 1-6 alkoxymethyl, tetrahydropyranyl, benzyl (hereinafter referred to as “Bn”), aralkyl such as p-methoxybenzyl, acyl such as formyl and acetyl, benzoyl and the like.
- Examples of the “carboxyl-protecting group” include C 1-6 alkyl such as methyl, ethyl, propyl, isopropyl and tert-butyl; C 1-6 haloalkyl such as 2,2,2-trichloroethyl; C 2-6 alkenyl such as aralkyl such as benzyl, p-methoxybenzyl, p-nitrobenzyl, benzhydryl, trityl and the like, and particularly methyl, ethyl, tert-butyl, 2-propenyl, benzyl, p-methoxy Benzyl, benzhydryl and the like are preferred.
- the introduction and removal of the protecting group can be carried out according to the method described in the above document [Protective Groups in Organic Synthesis] or a method analogous thereto.
- the compounds represented by the formula (I-1), formula (I-2) or formula (I-3) thus obtained can be easily isolated and purified by ordinary separation means.
- Examples of such means include solvent extraction, recrystallization, column chromatography, preparative thin layer chromatography and the like.
- Pharmacological test example 1 (LCE enzyme activity inhibition test) The test compound was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM and further diluted with DMSO to prepare a 1000-fold concentrated solution of the evaluation concentration.
- DMSO dimethyl sulfoxide
- the LCE enzyme activity inhibition test was performed by improving the method of Moon (J. Biol. Chem., 276, 45358-45366 (2001)).
- phosphate buffer solution 100 mM potassium phosphate buffer solution (pH 6.5)
- substrate solution 100 mM potassium phosphate buffer (pH 6.5)
- 4.0 ⁇ M rotenone 80 ⁇ M fatty acid-free bovine serum albumin, 160 ⁇ M palmitoyl CoA, 80 ⁇ M malonyl CoA, 3.5 ⁇ M [ 14 C] -malonyl CoA ( 1.92 GBq / mmol, manufactured by Amersham) was added to each well, and 25 ⁇ L of enzyme solution (100 mM potassium phosphate buffer (pH 6.5), 100 ⁇ g / mL human LCE) was added and the top of the plate was sealed with a seal And mild at 37 ° C for 90 minutes It was incubated with stirring crab shaking.
- the compounds according to the invention can be administered orally or parenterally and can be formulated into a form suitable for such administration, for example hypertension, angina pectoris, heart failure, myocardial infarction, stroke, lameness, Diabetic nephropathy, diabetic retinopathy, vision loss, electrolyte abnormalities, cardiovascular diseases such as arteriosclerosis, for example central nervous system diseases such as bulimia, diabetic neuropathy, such as metabolic syndrome, obesity, diabetes, Metabolic diseases such as insulin resistance, hyperlipidemia, hypercholesterolemia, hypertriglyceremia, dyslipidemia, nonalcoholic fatty liver, abnormal hormone secretion, gout, fatty liver, such as menstrual disorders, sex Reproductive system diseases such as dysfunction, liver dysfunction, pancreatitis, cholecystitis, gastrointestinal tract disease such as gastroesophageal reflux, obesity hypoventilation syndrome (Pickwick syndrome), respiratory apnea such as sleep apnea syndrome Disease, can be subjecte
- one aspect of the present invention provides a disease, disease or condition resulting from modulation of LCE comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof. It is to provide treatment or prevention of the condition.
- Another aspect of the present invention includes metabolic syndrome, fatty liver, hyperlipidemia, comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof. It is to provide a method for treating or preventing dyslipidemia, non-alcoholic fatty liver disease, obesity, diabetes, bulimia, malignant neoplasms or infectious diseases.
- Another aspect of the present invention is to provide a therapeutic or prophylactic method for diabetes comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof. It is.
- Another aspect of the present invention provides a method for treating or preventing obesity comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof. That is.
- Another aspect of the present invention is overeating, bulimia, hypertension, plasma insulin levels comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of a compound according to the present invention.
- Another aspect of the present invention is the treatment of hyperlipidemia or dyslipidemia comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of a compound according to the present invention. Is to provide a law or prevention.
- Another aspect of the present invention is to provide a caloric intake method comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof.
- Another aspect of the present invention is to provide a method for reducing food intake, comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof. .
- Another aspect of the present invention is to provide a method of increasing satiety comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof. .
- Another aspect of the present invention is to provide a method for reducing appetite, comprising administering a therapeutically or prophylactically effective amount of a compound according to the present invention to a subject in need thereof.
- the invention also treats obesity comprising administering a compound according to the invention in combination with a therapeutically or prophylactically effective amount of another agent known to be useful in the treatment or prevention of the condition.
- a compound according to the invention in combination with a therapeutically or prophylactically effective amount of another agent known to be useful in the treatment or prevention of the condition.
- the present invention also provides a method for treating diabetes comprising administering a compound according to the present invention in combination with a therapeutically or prophylactically effective amount of another drug known to be useful in the treatment or prevention of the condition. Or it relates to prevention methods.
- Another aspect of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising the compound according to the present invention and a pharmaceutically acceptable carrier.
- Still another aspect of the present invention relates to the use of a compound according to the present invention for the manufacture of a medicament useful for the treatment, prevention, or suppression of diseases caused by LCE in a subject in need thereof.
- Yet another aspect of the invention is the metabolic syndrome, hyperlipidemia, dyslipidemia, non-alcoholic fatty liver, obesity, diabetes, bulimia, malignant neoplasm or infection of the subject in need thereof It relates to the use of a compound according to the invention for the manufacture of a medicament useful for the treatment or prevention of sexually transmitted diseases.
- Still another aspect of the present invention relates to the use of a compound according to the present invention for the manufacture of a medicament useful for the treatment or prevention of obesity in a subject in need thereof.
- Still another aspect of the present invention relates to the use of a compound according to the present invention for the manufacture of a medicament useful for the treatment or prevention of diabetes in a subject in need thereof.
- Yet another aspect of the present invention relates to the use of a compound according to the present invention for the manufacture of a medicament useful for the treatment or prevention of hyperlipidemia or dyslipidemia in a subject in need thereof.
- a therapeutically effective amount of a compound according to the present invention an insulin sensitizer, an insulin analog, a sulfonylurea, an ⁇ -glucosidase inhibitor, dipeptidyl peptidase 4 (DPP- 4 or DP-IV) inhibitor, glucagon-like peptide 1 (GLP-1) agonist, HMG-CoA reductase inhibitor, serotonin-like substance, ⁇ 3-adrenergic receptor agonist, neuropeptide Y1 antagonist, neuropeptide Y2 Agonist, neuropeptide Y5 antagonist, pancreatic lipase inhibitor, cannabinoid CB1 receptor antagonist or inverse agonist, melanin-concentrating hormone receptor agonist, melanocortin 4 receptor agonist, bombesin receptor subtype 3 agonist, ghrelin consisting antagonist, PYY, PYY 3-36 and NK-1 antagonist
- a therapeutically effective amount of a more selected an insulin sensitizer, an insulin analog, a
- a therapeutically effective amount of a compound according to the present invention an insulin sensitizer, an insulin analog, a sulfonylurea, an ⁇ -glucosidase inhibitor, dipeptidyl peptidase 4 (DPP- 4 or DP-IV) inhibitor, glucagon-like peptide 1 (GLP-1) agonist, HMG-CoA reductase inhibitor, serotonin-like substance, ⁇ 3-adrenergic receptor agonist, neuropeptide Y1 antagonist, neuropeptide Y2 Agonist, neuropeptide Y5 antagonist, pancreatic lipase inhibitor, cannabinoid CB1 receptor antagonist or inverse agonist, melanin-concentrating hormone receptor agonist, melanocortin 4 receptor agonist, bombesin receptor subtype 3 agonist, ghrelin consisting antagonist, PYY, PYY 3-36 and NK-1 antagonist
- a therapeutically effective amount of a more selected an insulin sensitizer, an insulin analog, a
- a therapeutically effective amount of a compound according to the present invention an insulin sensitizer, an insulin analog, a sulfonylurea, an ⁇ -glucosidase inhibitor, dipeptidyl peptidase 4 (DPP- 4 or DP-IV) inhibitor, glucagon-like peptide 1 (GLP-1) agonist, HMG-CoA reductase inhibitor, serotonin-like substance, ⁇ 3-adrenergic receptor agonist, neuropeptide Y1 antagonist, neuropeptide Y2 Agonist, neuropeptide Y5 antagonist, pancreatic lipase inhibitor, cannabinoid CB1 receptor antagonist or inverse agonist, melanin-concentrating hormone receptor agonist, melanocortin 4 receptor agonist, bombesin receptor subtype 3 agonist, ghrelin consisting antagonist, PYY, PYY 3-36 and NK-1 antagonist Combination for simultaneous, separate or sequential use of obesity, diabetes
- Yet another aspect of the present invention comprises a therapeutically effective amount of a compound according to the present invention and simvastatin, mevastatin, ezetimibe, atorvastatin, sitagliptin, metformin, sibutramine, orlistat, Qnexa (trade name) and phentermine.
- a therapeutically effective amount of an agent selected from the group or a pharmaceutically acceptable salt thereof for the treatment of obesity, diabetes, diabetes-related diseases or obesity-related diseases in a subject in need thereof; The above use for the manufacture of a medicament useful for management or prevention.
- a pharmaceutically acceptable additive in accordance with its administration form and administer it after various preparations.
- various additives that are usually used in the pharmaceutical field can be used.
- dosage forms formulated as a mixture with these additives include solid preparations such as tablets, capsules, granules, powders or suppositories; or liquid preparations such as syrups, elixirs or injections, etc. These can be prepared according to conventional methods in the pharmaceutical field.
- a liquid preparation it may be dissolved or suspended in water or other appropriate medium at the time of use.
- injections they may be dissolved or suspended in physiological saline or glucose solution as necessary, and buffering agents and preservatives may be added.
- the compound according to the present invention is effective for animals and plants including humans or other mammals that require treatment with the compound.
- the mammal is preferably a human and may be male or female.
- mammals other than humans include pets such as dogs and cats.
- the compound according to the present invention is also effective against obesity such as dogs and cats or diseases related to obesity. Whether or not treatment with the compound is required can be readily determined by a regular physician, veterinarian or clinician.
- the dose and the number of administrations vary depending on the sex, age, weight, degree of symptoms of the patient, and the type and range of the intended treatment effect.
- 0.01 to 100 mg / kg, preferably 0.03 to 1 mg / kg per day for an adult is divided into 1 to several times, and in the case of parenteral administration, 0.001 to 10 mg / kg.
- 1.0-1000 mg of active ingredient especially 1.0, 5.0, 10.0, 15.0, 20 to adjust the dosage to the condition of the patient being treated.
- 0.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0 800.0, 900.0 and 1000.0 mg tablets containing 1000.0 mg of the active ingredient are preferred.
- the compounds can be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
- the compounds according to the invention are applied for the treatment or prevention of obesity and / or diabetes and / or hyperlipidemia and / or dyslipidemia and / or non-alcoholic fatty liver, or other diseases
- the daily dose of the compound of the present invention is about 0.1 mg to about 100 mg per kg body weight of the animal, it is more preferable to administer a single dose or divided dose of 2 to 6 times per day, or gradually. Satisfactory results can generally be obtained when using a releasable formulation.
- the total daily dose is from about 1.0 mg to about 1000 mg, preferably from about 1 mg to about 50 mg.
- the total daily dose will usually be from about 7 mg to about 350 mg.
- This dosage regimen can be adjusted to provide the best therapeutic effect. Ordinary physicians, veterinarians or clinicians can easily determine and handle the effective amount of drug needed to treat, prevent, prevent, inhibit or stop disease progression.
- These preparations can contain the compound according to the present invention in a ratio of 1.0 to 100% by weight, preferably 1.0 to 60% by weight of the total drug. These formulations may also contain other therapeutically effective compounds.
- cardiovascular diseases such as hypertension, angina pectoris, heart failure, myocardial infarction, stroke, lameness, diabetic nephropathy, diabetic retinopathy, vision loss, electrolyte abnormalities, arteriosclerosis, such as bulimia
- Central nervous system diseases such as diabetic neuropathy, eg metabolic syndrome, obesity, diabetes, insulin resistance, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, nonalcoholic fat Metabolic diseases such as liver, hormonal secretion abnormalities, gout, fatty liver, reproductive system diseases such as menstrual disorders, sexual dysfunction, liver dysfunction, pancreatitis, cholecystitis, gastrointestinal diseases such as gastroesophageal reflux, low obesity
- respiratory diseases such as ventilation syndrome (Pickwick syndrome), sleep apnea syndrome, infectious diseases caused by bacteria, fungi, and parasites, malignant neoplasms, arthritis, inflammatory diseases such as skin ulcers, etc.
- the present invention should be construed to include all simultaneous or timed administrations, and administration in the present invention should be construed as such.
- the range of combinations of the compounds of the present invention with other agents useful for the treatment of the above-mentioned diseases includes, in principle, combinations with any pharmaceutical preparations useful for the treatment of the above-mentioned diseases.
- the combination includes not only one other active substance but also two or more other active substances in combination with the composition of the present invention.
- combinations of the composition of the present invention with one, two or more activators selected from the above therapeutic agents For example, for the purpose of treatment / management / prevention of metabolic syndrome, one, two or more activators selected from the composition of the present invention and a hyperlipidemic agent, a lipid-reducing agent and an anti-diabetic agent The combination with is beneficial.
- compositions comprising anti-obesity agents and anti-hypertensive agents have a synergistic effect on the treatment, management or prevention of metabolic syndrome To do.
- drugs combined with this drug include ACAT inhibitor, ⁇ -procker, aldose reductase inhibitor, ⁇ -amylase inhibitor, angiotensin converting enzyme inhibitor, angiotensin receptor antagonist, anion exchange resin, appetite suppressant, antioxidant Agent, antiplatelet agent, beta blocker, biguanide agent, calcium antagonist, CB1 receptor inverse agonist / antagonist, CETP inhibitor, cholesterol absorption inhibitor, DGAT inhibitor, DP-IV inhibitor, diuretic, eicosapentaenoic acid , Endothelin antagonist, FLAP inhibitor, FXR modulator, ghrelin antagonist, GLP-1 agonist, GLP-1 secretion agent, glucagon antagonist, glucokinase activator, glucocorticoid receptor ligand, ⁇ -glycosidase inhibitor, GPAT inhibition Agent, histami H3 receptor ligand, HMG-CoA reductase inhibitor, HSD inhibitor, insulin and its similar drugs, kinase
- the compound according to the present invention has an excellent LCE inhibitory action, and various diseases involving LCE such as cardiovascular disease, nervous system disease, metabolic disease, reproductive system disease, gastrointestinal disease, neoplasm, infection It is useful as a therapeutic agent for diseases, etc., or as a herbicide.
- Thin-layer chromatography used Silica gel 60 F 254 (Merck) as a plate and a UV detector as a detection method.
- column silica gel Wakogel TM C-300 or C-200 (Wako Pure Chemical Industries), FLASH + cartridge (Biotage) or Chromatorex (FUJI SILYSIA CHEMICAL) was used.
- MS spectra were measured using ZQ2000 (Waters). When NMR spectra are measured with a deuterated dimethyl sulfoxide solution, dimethyl sulfoxide is used as an internal standard, and JNM-AL400 (JEOL), Mercury 400 (400 MHz; Varian), or Inova 400 (400 MHz; Varian) type spectrometer. The total ⁇ value was expressed in ppm.
- (1R *, 3R *) means a 1: 1 mixture of (1R, 3R) and (1S, 3S), and (1R *, 3S *) means (1R, 3S) and (1S, 3R) It shall mean a 1: 1 mixture.
- Reference example 1 3- ⁇ [(4-Isopropoxyphenyl) amino] carbonyl ⁇ cyclohexyl methanesulfonate
- reaction solution was returned to room temperature, diluted with ethyl acetate, and washed twice with distilled water and once with saturated brine.
- the organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- the obtained residue was purified by silica gel column chromatography to obtain the desired product (252 mg, 79%).
- the compound according to the present invention has an excellent LCE inhibitory action, and is a therapeutic agent or herbicidal agent for various diseases involving LCE, such as cardiovascular diseases, nervous system diseases, metabolic diseases, reproductive system diseases, gastrointestinal diseases. Useful as an agent.
Abstract
Description
J.Lipid Res.,43(6),911-920頁(2002年) Cell,126:691-699頁(2006年)
(1) 式(I)
Yは、CR3又はNを表し、但しYが、Nを表す場合、(II-2)又は(II-3)においてnは、0又は2を表し、
R1は、C1-6アルキル、C3-8シクロアルキル、アリール又はヘテロアリールを表し、該アルキル、シクロアルキル、アリール又はヘテロアリールは、ヒドロキシ、シアノ、カルボキシル、スルホ、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C3-8シクロアルキル、C1-6アルコキシ、ハロC1-6アルコキシ、アミノ(該アミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、カルバモイル(該カルバモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、スルファニル(該スルファニルは、C1-6アルキル、アリール若しくはヘテロアリールで1置換されていてもよい)、C1-6アルキルスルフィニル、アリールスルフィニル、ヘテロアリールスルフィニル、C1-6アルキルスルホニル、アリールスルホニル、ヘテロアリールスルホニル、スルファモイル(該スルファモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルキルスルホニルアミノ、アリールスルホニルアミノ、ヘテロアリールスルホニルアミノ、C1-6アルキルカルボニル、アリールカルボニル、ヘテロアリールカルボニル、C1-6アルコキシカルボニル、アリールオキシカルボニル、ヘテロアリールオキシカルボニル、カルバモイルアミノ(該カルバモイルアミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルコキシカルボニルアミノ、アリールオキシカルボニルアミノ、ヘテロアリールオキシカルボニルアミノ、C1-6アルキルカルボニルアミノ、アリールカルボニルアミノ、ヘテロアリールカルボニルアミノ、アリール、ヘテロアリール、アラルキル、ヘテロアラルキル、アラルキルオキシ及びヘテロアラルキルオキシからなる群から選択される置換基で置換されていてもよく、
R2は、フェニル又はヘテロアリールを表し、該フェニル又はヘテロアリールは、ヒドロキシ、シアノ、カルボキシル、スルホ、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C3-8シクロアルキル、C1-6アルコキシ、ハロC1-6アルコキシ、アミノ(該アミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、カルバモイル(該カルバモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、スルファニル(該スルファニルは、C1-6アルキル、アリール若しくはヘテロアリールで1置換されていてもよい)、C1-6アルキルスルフィニル、アリールスルフィニル、ヘテロアリールスルフィニル、C1-6アルキルスルホニル、アリールスルホニル、ヘテロアリールスルホニル、スルファモイル(該スルファモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルキルスルホニルアミノ、アリールスルホニルアミノ、ヘテロアリールスルホニルアミノ、C1-6アルキルカルボニル、アリールカルボニル、ヘテロアリールカルボニル、C1-6アルコキシカルボニル、アリールオキシカルボニル、ヘテロアリールオキシカルボニル、カルバモイルアミノ(該カルバモイルアミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルコキシカルボニルアミノ、アリールオキシカルボニルアミノ、ヘテロアリールオキシカルボニルアミノ、C1-6アルキルカルボニルアミノ、アリールカルボニルアミノ、ヘテロアリールカルボニルアミノ、アリール、ヘテロアリール、アラルキル、ヘテロアラルキル、アラルキルオキシ及びヘテロアラルキルオキシからなる群から選択される置換基で置換されていてもよく、
R3及びR4は、それぞれ独立して、水素原子、C1-6アルキル、C3-8シクロアルキル、アラルキル、ヘテロアラルキル、アリール又はヘテロアリールを表し、該アルキル、シクロアルキル、アラルキル、ヘテロアラルキル、アリール又はヘテロアリールは、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C1-6アルコキシ及びハロC1-6アルコキシからなる群から選択される置換基で置換されていてもよく、
M1、M2、M3及びM4は、それぞれ独立して、水素原子若しくはハロゲンで置換されていてもよいC1-6アルキルを表すか、或いはM1が、M2、M3又はM4と一緒になって、-CH2-若しくは-CH2-CH2-を形成するか、又はM4が、M2と一緒になって、-CH2-若しくは-CH2-CH2-を形成する]
で表される化合物又は薬学的に許容されるその塩(以下、「本発明の化合物」という)を提供する。
(2) 式(I)で表される化合物又は薬学的に許容されるその塩を有効成分とする長鎖脂肪酸伸長酵素(LCE)阻害剤、
(3) 式(I)で表される化合物又は薬学的に許容されるその塩を含有する医薬組成物、
(4) 式(I)で表される化合物又は薬学的に許容されるその塩を有効成分とする、糖尿病、肥満症又は非アルコール性脂肪肝の予防剤又は治療剤、をも提供する。
フェニル、2-フルオロフェニル、3-フルオロフェニル、4-フルオロフェニル、2-クロロフェニル、3-クロロフェニル、4-クロロフェニル、2-メトキシフェニル、3-メトキシフェニル、4-メトキシフェニル、2-メチルフェニル、3-メチルフェニル、4-メチルフェニル、2-イソプロピルフェニル、3-イソプロピルフェニル、4-イソプロピルフェニル、2-イソプロピルフェニル、3-イソプロピルフェニル、4-イソプロピルフェニル、2-イソプロポキシフェニル、3-イソプロポキシフェニル、4-イソプロポキシフェニル、2-ベンジルフェニル、3-ベンジルフェニル、4-ベンジルフェニル、2-ベンジロキシフェニル、3-ベンジロキシフェニル、4-ベンジロキシフェニル、5-イソプロポキシフェニルピリジン-2-イル、6-イソプロポキシフェニルピリジン-3-イル、5-イソプロポキシピリミジン-2-イル、3-メトキシピリジン-2-イル、3-シクロプロピル-1H-ピラゾール-5-イル、5-イソプロポキシ-1H-ピラゾール-3-イルが推奨される。
1) M1が、M2と一緒になって、-CH2-若しくは-CH2-CH2-を形成し、そしてM3及びM4は、それぞれ独立して、水素原子若しくは場合によりハロゲンで置換されていてもよいC1-6アルキルであるもの、
2) M1が、M3と一緒になって、-CH2-若しくは-CH2-CH2-を形成し、そしてM2及びM4は、それぞれ独立して、水素原子若しくは場合によりハロゲンで置換されていてもよいC1-6アルキルであるもの、
3) M1が、M4と一緒になって、-CH2-若しくは-CH2-CH2-を形成し、そしてM2及びM3は、それぞれ独立して、水素原子若しくは場合によりハロゲンで置換されていてもよいC1-6アルキルであるもの、
4) M4が、M2と一緒になって、-CH2-若しくは-CH2-CH2-を形成し、そしてM1及びM3は、それぞれ独立して、水素原子若しくは場合によりハロゲンで置換されていてもよいC1-6アルキルであるもの、
5) M1、M2、M3及びM4のすべてが水素原子であるもの、
6) M1、M2、M3及びM4のうちいずれか1つが、場合によりハロゲンで置換されていてもよいC1-6アルキルであり、他が水素原子であるもの、
7) M1、M2、M3及びM4のうちいずれか2つが、場合によりハロゲンで置換されていてもよいC1-6アルキルであり、他が水素原子であるもの、等が例示され、特にM1、M2、M3及びM4が何れも水素原子が推奨される。
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3S*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(ピリミジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(1,3-チアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(1,3,4-チアジアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-[(1-メチル-1H-イミダゾール-2-イル)スルホニル]シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリジン-4-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリミジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(1,3-チアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-3-(ブチルスルホニル)-N-(5-イソプロポキシピリジン-2-イル)シクロヘキサンカルボキサミド、
(1R*,3R*-N-(5-イソプロポキシピリジン-2-イル)-3-(ピラジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3S*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)ピペリジン-1-カルボキサミド等が例示され、好ましくは
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリミジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(1,3-チアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド等が推奨される。
本発明に係る化合物は、例えば下記の製造方法又は実施例に示す方法により製造することができる。ただし、本発明に係る化合物の製造方法はこれらの例に限定されるものではない。
式(I-1)で表される化合物は、以下の方法で調製可能である。
化合物1を、有機溶媒中、化合物2とアミド化反応を行い、化合物3を得る。
化合物3を、反応溶媒中で公知の方法により還元を行い、化合物4とする。
化合物4をメシル化することにより、化合物5を得る。メシル化の方法は特に限定されないが、例えば、メシル化試薬としてメシルクロリドを、塩基としてトリエチルアミンを組み合わせた方法により行うことができる。
化合物5を、反応溶媒中、塩基の存在下で化合物6と反応を行い、化合物7を得る。
化合物7を酸化することにより、式(I-1)で表される化合物を得る。
製造方法2は、化合物1’を原料とした式(I-1)で表される化合物の別途合成方法である。
化合物1’をメシル化することにより、化合物8を得る。メシル化の方法は、工程3に準じて行うことができる。
化合物8を化合物6と反応を行い、化合物9を得る。この反応は、工程4に準じて行うことができる。
化合物9を酸化することにより、化合物10を得る。酸化の方法は、工程5に準じる。
化合物10のエステルを加水分解することにより、化合物11とする。加水分解の方法は特に限定されないが、例えばメタノール、エタノール等の有機溶媒中、水酸化ナトリウム水溶液又は水酸化カリウム水溶液等を用いて室温から溶媒の沸点までの温度で行うことができる。
化合物11を反応溶媒中、化合物2と反応を行い、式(I-1)で表される化合物を得る。反応方法は、工程1に準じて行うことができる。
製造方法3は、式(I-1a)で表される化合物の製造方法である。
化合物12を、反応溶媒中、化合物6と反応を行い、化合物13を得る。反応方法は、工程4に準じる。
化合物13を酸化することにより化合物14を得る。酸化の方法は、工程5に準じる。
化合物14のアミノ保護基を脱保護して化合物15とする。脱保護の方法としては、プロテクティブ・グループス・イン・オーガニック・シンセシス(Protective Groups in Organic Synthesis)、T.W.グリーン(T.W.Greene)著、John Wiley & Sons社(1981年))に記載の方法又はそれに準じる方法により行うことができる。保護基としては、tert-ブチルオキシカルボニル、ベンジルオキシカルボニル、p-メトキシベンジルオキシカルボニル等が例示される。
化合物15を、有機溶媒中、化合物16と反応を行い、式(I-1a)で表される化合物を得る。
製造方法4は、化合物10を原料とする、式(I-2)で表される化合物の製造方法である。
化合物10を、水素化リチウムアルミニウム、水素化ホウ素ナトリウム等の還元剤を用いて従来公知の方法でエステル部分の還元を行い、化合物17を得る。
化合物17とフタルイミドとを、光延反応により縮合し化合物18を得る。
化合物18を反応溶媒中、ヒドラジン処理を行い化合物19とする。
化合物19を工程1に準じて化合物20と縮合を行い、式(I-2)で表される化合物を得る。
化合物19を反応溶媒中、塩基の存在下、化合物21と反応を行い、式(I-3)で表される化合物を得る。
被検化合物をジメチルスルホキシド(DMSO)に10mMとなるように溶解し、更にDMSOで希釈し、評価濃度の1000倍濃縮溶液を作製した。LCE酵素活性阻害試験はMoon(J.Biol.Chem.,276巻,45358-45366頁(2001年))らの方法を改良して行った。すなわち、希釈した被検化合物を96ウェルアッセイプレート(Corning、96ウェルアッセイブロック)へ1ウェルあたり1.0μL添加した後、50μLのリン酸緩衝溶液(100mM リン酸カリウム緩衝溶液(pH6.5))、25μLの基質溶液(100mM リン酸カリウム緩衝溶液(pH6.5)、4.0μM rotenone、80μM 脂肪酸不含ウシ血清アルブミン、160μM パルミトイルCoA、80μM マロニルCoA、3.5μM[14C]-マロニルCoA(1.92GBq/ミリモル、Amersham製))を各ウェルに加え、更に25μLの酵素溶液(100mM リン酸カリウム緩衝溶液(pH6.5)、100μg/mL ヒトLCE)を添加してプレート上部をシールで密閉し、37℃で90分間穏やかに振盪攪拌しながらインキュベーションした。その後、各ウェルに100μLの5N HClを添加して室温で5分間アッセイプレートを攪拌して酵素反応を停止させるとともにアシルCoAを加水分解した。その後、各ウェルの酵素反応溶液をあらかじめ水を通液させておいた96ウェルGF/Cフィルタープレート(PerkinElmer ユニフィルター96GF/C)の各ウェルに吸着させ、各ウェルを水で洗浄し非吸着のマロニルCoAを除去した後、50℃で60分間GF/Cフィルタープレートを乾燥させた。その後、各ウェルに30μLのシンチレーター(PerkinElmer マイクロシンチ0)を加えてプレート上部をシールし、固定された[14C]の放射活性をマイクロプレートシンチレーションカウンター(PerkinElmer トップカウント)で測定し酵素活性とした。被検化合物によるヒトLCEの酵素阻害活性は被検化合物を含まないDMSO添加のウェルにおける放射活性をコントロールとして算出した。本発明化合物の活性を本アッセイを用いて調べたところ、それらの化合物はヒトLCEの活性を阻害した。結果を表1に示す。
通常の内科医、獣医又は臨床医は病状進行を治療し、予防し、阻止し、抑制し又は停止させるに必要な効果的薬物量を容易に決定し処理することができる。
s:シングレット
d:ダブレット
dd:ダブル ダブレット
t:トリプレット
dt:ダブル トリプレット
q:クァルテット
m:マルチプレット
br:ブロード
J:カップリング定数
Hz:ヘルツ
DMSO-d6:重ジメチルスルホキシド
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド、および(1R*,3S*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド
参考例1の表題化合物(85mg、0.239ミリモル)及びチオフェノール(119mg、1.078ミリモル)のDMF(3mL)溶液に炭酸カリウム(149mg、1.078ミリモル)及びヨウ化カリウム(179mg、1.078ミリモル)を加え80度で24時間攪拌した。室温にもどし、酢酸エチルを加え、蒸留水にて3度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(56mg、64%)を得た。
(2)表題化合物の合成
上記(1)で得られた化合物(49mg、0.133ミリモル)のクロロホルム(2mL)溶液中にm-クロロ過安息香酸(69%含有)(83mg、0.332ミリモル)を加え、室温で5時間攪拌した。飽和チオ硫酸ナトリウム水溶液を加えしばらく攪拌した。有機層を飽和重炭酸ナトリウム水溶液反応溶液にて2度洗浄後、硫酸マグネシウムにて乾燥し、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド(21.4mg、40%)と(1R*,3S*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド(1.9mg、3.5%)をそれぞれ得た。
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド:
1H-NMR(400MHz,CDCl3,δ):1.31(6H,d,J=6.3Hz),1.67-1.78(3H,m),1.83-1.99(4H,m),2.20-2.29(1H,m),2.84-2.93(1H,m),3.61-3.72(1H,m),4.42-4.54(1H,m),6.80-6.86(2H,m),7.21(1H,s),7.31-7.36(2H,m),7.53-7.59(2H,m),7.62-7.68(1H,m),7.88-7.92(2H,m).
ESI-MS(m/z):402.2[M+H]+
(1R*,3S*)-N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド:
1H-NMR(400MHz,CDCl3,δ):1.31(6H,d,J=6.3Hz),1.67-1.78(3H,m),1.83-1.99(4H,m),2.20-2.29(1H,m),2.84-2.93(1H,m),3.61-3.72(1H,m),4.42-4.54(1H,m),6.80-6.86(2H,m),7.21(1H,s),7.31-7.36(2H,m),7.53-7.59(2H,m),7.62-7.68(1H,m),7.88-7.92(2H,m).
ESI-MS(m/z):402.1[M+H]+
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド
参考例1の表題化合物と2-メルカプトピリジンを用いて実施例1(1)に準じた方法により表題化合物を合成した。
(2)表題化合物の合成
上記(1)で合成した化合物を用いて実施例1(2)に準じた方法で表題化合物を得た。
1H-NMR(400MHz,CDCl3,δ):1.29-1.33(6H,m),1.68-1.78(1H,m),1.80-2.01(5H,m),2.09-2.18(1H,m),2.20-2.29(1H,m),2.86-2.98(1H,m),4.06-4.17(1H,m),4.42-4.55(1H,m),6.78-6.89(2H,m),7.18-7.22(1H,m),7.33-7.42(2H,m),7.51-7.59(1H,m),7.94-8.00(1H,m),8.09-8.14(1H,m),8.73-8.78(1H,m).
ESI-MS(m/z):403.2[M+H]+
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(ピリミジン-2-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.31(6H,d,J=6.3Hz),1.73-1.80(1H,m),1.83-1.89(2H,m),1.90-2.02(2H,m),2.04-2.20(2H,m),2.24-2.34(1H,m),2.90-2.99(1H,m),4.31-4.39(1H,m),4.43-4.54(1H,m),6.79-6.88(2H,m),7.30-7.41(3H,m),7.53-7.59(1H,m),8.93-8.99(2H,m).
ESI-MS(m/z):404.0[M+H]+
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(1,3-チアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.31(6H,d,J=5.9Hz),1.71-1.79(1H,m),1.80-1.94(3H,m),1.95-2.08(2H,m),2.10-2.18(1H,m),2.31-2.40(1H,m),2.88-2.95(1H,m),4.00-4.10(1H,m),4.43-4.54(1H,m),6.80-6.86(2H,m),7.33-7.39(2H,m),7.72-7.76(1H,m),8.03-8.08(1H,m).
ESI-MS(m/z):409.0[M+H]+
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-(1,3,4-チアジアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.27(7H,d,J=6.3Hz),1.68-1.80(2H,m),1.83-1.98(3H,m),2.07-2.18(2H,m),2.39-2.48(1H,m),2.83-2.91(1H,m),4.16-4.25(1H,m),4.41-4.51(1H,m),6.76-6.85(2H,m),7.24-7.28(1H,m),7.30-7.37(2H,m),9.35-9.37(1H,m).
ESI-MS(m/z):410.0[M+H]+
(1R*,3R*)-N-(4-イソプロポキシフェニル)-3-[(1-メチル-1H-イミダゾール-2-イル)スルホニル]シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.31(6H,d,J=5.9Hz),1.59-1.80(2H,m),1.82-1.96(2H,m),2.04-2.18(3H,m),2.38-2.51(1H,m),2.89-2.98(1H,m),3.94-4.04(4H,m),4.44-4.55(1H,m),6.81-6.88(2H,m),7.01-7.06(1H,m),7.12-7.16(1H,m),7.41-7.47(2H,m),7.98-8.07(1H,m).
ESI-MS(m/z):406.0[M+H]+
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド
参考例2の表題化合物とチオフェノールを用いて、実施例2(1)に準じた方法により表題化合物を合成した。
(2)表題化合物の合成
上記(1)で合成した化合物(39.5mg、0.107ミリモル)のアセトン(0.75mL)-蒸留水(0.75mL)の混合溶液に、酢酸(30.5μL、0.535ミリモル)と過マンガン酸カリウム(50.5mg、0.321ミリモル)を加え、室温にて19時間攪拌した。反応溶液の大部分を減圧濃縮後、残渣にクロロホルムと飽和重炭酸ナトリウム水溶液を加え、クロロホルムにて3度抽出した。有機層を集め、硫酸マグネシウムにて乾燥し、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、表題化合物(19mg、44%)を得た。
1H-NMR(400MHz,CDCl3,δ):1.33(6H,d,J=6.3Hz),1.55-1.79(3H,m),1.81-2.00(4H,m),2.24-2.33(1H,m),2.87-2.95(1H,m),3.65-3.74(1H,m),4.45-4.56(1H,m),7.20-7.25(1H,m),7.53-7.59(2H,m),7.62-7.68(1H,m),7.88-7.93(3H,m),7.96-8.00(1H,m),8.01-8.07(1H,m).
ESI-MS(m/z):403.0[M+H]+
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.33(6H,d,J=5.9Hz),1.63-1.74(1H,m),1.78-1.99(5H,m),2.01-2.11(1H,m),2.21-2.31(1H,m),2.91-3.01(1H,m),4.10-4.20(1H,m),4.46-4.56(1H,m),7.21-7.25(1H,m),7.52-7.59(1H,m),7.91-8.03(3H,m),8.05-8.14(2H,m),8.77-8.82(1H,m).
ESI-MS(m/z):404.0[M+H]+
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリジン-4-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.33(6H,d,J=6.3Hz),1.55-1.78(3H,m),1.80-1.89(2H,m),1.90-2.05(2H,m),2.23-2.31(1H,m),2.86-2.95(1H,m),3.78-3.88(1H,m),4.44-4.56(1H,m),7.21-7.25(1H,m),7.76-7.80(2H,m),7.90-7.93(1H,m),7.99-8.06(2H,m),8.88-8.95(2H,m).
ESI-MS(m/z):404.0[M+H]+
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリミジン-2-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.34(6H,d,J=6.3Hz),1.67-1.75(1H,m),1.77-1.87(1H,m),1.90-2.04(3H,m),2.06-2.18(2H,m),2.34-2.43(1H,m),2.94-3.05(1H,m),4.30-4.40(1H,m),4.45-4.56(1H,m),7.21-7.28(1H,m),7.54-7.61(1H,m),7.91-7.96(1H,m),8.08-8.18(2H,m),8.99-9.05(2H,m).
ESI-MS(m/z):405.0[M+H]+
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(1,3-チアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):1.33(6H,d,J=6.3Hz),1.65-1.97(5H,m),2.03-2.13(2H,m),2.34-2.44(1H,m),2.91-2.99(1H,m),4.04-4.13(1H,m),4.46-4.56(1H,m),7.21-7.25(1H,m),7.73-7.77(1H,m),7.91-7.94(1H,m),8.01-8.10(3H,m).
ESI-MS(m/z):410.0[M+H]+
(1R*,3R*)-3-(ブチルスルホニル)-N-(5-イソプロポキシピリジン-2-イル)シクロヘキサンカルボキサミド
1H-NMR(400MHz,CDCl3,δ):0.88(3H,t,J=7.3Hz),1.33(6H,d,J=6.3Hz),1.35-1.46(2H,m),1.50-1.61(1H,m),1.63-1.84(4H,m),1.86-2.07(3H,m),2.15-2.26(1H,m),2.89-3.07(2H,m),3.13-3.26(2H,m),4.46-4.56(1H,m),7.19-7.25(1H,m),7.93-7.99(1H,m),8.03-8.09(1H,m),8.36-8.44(1H,m).
ESI-MS(m/z):383.0[M+H]+
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピラジン-2-イルスルホニル)シクロヘキサンカルボキサミド
参考例2の表題化合物(60mg、0.168ミリモル)、2-メルカプトピラジン(113mg、1.010ミリモル)および炭酸セシウム(329mg、1.010ミリモル)をDMF(1mL)中で80度で5時間攪拌した。反応系の温度を室温に戻し、酢酸エチルを加え、蒸留水にて2度、飽和食塩水にて1度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物を得た。
(2)表題化合物の合成
上記(1)で合成した化合物を用いて、実施例7(2)に準じた方法により、表題化合物を得た。
1H-NMR(400MHz,CDCl3,δ):1.34(6H,d,J=5.9Hz),1.62-1.75(1H,m),1.77-1.95(4H,m),1.98-2.07(2H,m),2.26-2.35(1H,m),2.92-3.01(1H,m),4.08-4.24(1H,m),4.45-4.57(1H,m),7.21-7.26(1H,m),7.90-7.96(1H,m),8.02-8.12(2H,m),8.76-8.81(1H,m),8.85-8.90(1H,m),9.29-9.34(1H,m).
ESI-MS(m/z):405.2[M+H]+
(1R*,3R*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミドおよび(1R*,3S*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド
(1R*,3R*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド:
1H-NMR(400MHz,CDCl3,δ):1.31-1.38(6H,m),1.65-1.78(2H,m),1.79-2.02(3H,m),2.13-2.20(2H,m),2.22-2.31(1H,m),3.06-3.17(1H,m),4.04-4.11(1H,m),5.94(1H,s),7.54-7.63(1H,m),7.94-8.01(1H,m),8.07-8.15(1H,m),8.74-8.80(1H,m),10.09(1H,brs).
ESI-MS(m/z):393.2[M+H]+
(1R*,3S*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド:
1H-NMR(400MHz,CDCl3,δ):1.34(7H,d,J=6.3Hz),1.39-1.64(3H,m),1.76-1.88(1H,m),1.92-2.07(2H,m),2.10-2.17(1H,m),2.19-2.37(2H,m),3.52-3.66(1H,m),4.55-4.66(1H,m),5.65(1H,s),7.55-7.61(1H,m),7.94-8.02(1H,m),8.08-8.14(1H,m),8.41(1H,brs),8.74-8.80(1H,m).
ESI-MS(m/z):393.2[M+H]+
N-(4-イソプロポキシフェニル)-3-(フェニルスルホニル)ピペリジン-1-カルボキサミド
公知文献(WO96/39407号)記載の方法により合成されたベンジル3-[(メチルスルホニル)オキシ]ピペリジン-1-カルボン酸とチオフェノールを用いて実施例1(1)に準じた方法により表題化合物を合成した。
(2)ベンジル3-(フェニルスルホニル)ピペリジン-1-カルボン酸の合成
上記(1)で合成したベンジル3-(フェニルチオ)ピペリジン-1-カルボン酸を用いて、実施例1(2)に準じた方法により表題化合物を合成した。
(3)3-(フェニルスルホニル)ピペリジンの合成
上記(2)で合成した化合物(84mg、0.234ミリモル)のメタノール(2mL)溶液に10%パラジウム炭素触媒(40mg)を加え、水素存在下室温で18時間攪拌した。反応液をセライトにてろ過し、ろ液を濃縮した。得られた残渣を酢酸エチルにて溶解後、1規定水酸化ナトリウム水溶液にて1度、飽和食塩水にて1度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮し、目的物(43mg、82%)を得た。
(4)表題化合物の合成
上記(3)で合成した化合物(43mg、0.191ミリモル)のクロロホルム(3mL)溶液にトリエチルアミン(0.08mL、0.573ミリモル)とフェニル(4-イソプロポキシフェニル)カーバメート(67.3mg、0.248ミリモル)を加え、80度にて24時間攪拌した。反応系を室温に戻し、1規定水酸化ナトリウム水溶液にて1度、飽和食塩水にて1度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、表題化合物(45.7mg、59%)を得た。
1H-NMR(400MHz,CDCl3,δ):1.30(6H,d,J=5.9Hz),1.49-1.61(1H,m),1.77-1.93(2H,m),2.16-2.25(1H,m),2.88-2.98(1H,m),3.06-3.20(2H,m),3.82-3.89(1H,m),4.27-4.34(1H,m),4.43-4.51(1H,m),6.31(1H,brs),6.78-6.84(2H,m),7.13-7.19(2H,m),7.55-7.63(2H,m),7.66-7.72(1H,m),7.86-7.94(2H,m).
ESI-MS(m/z):403.3[M+H]+
3-{[(4-イソプロポキシフェニル)アミノ]カルボニル}シクロヘキシルメタンスルホネート
3-オキソ-1-シクロヘキサンカルボン酸(100mg、0.703ミリモル)のDMF(3mL)溶液に4-イソプロポキシアニリン(117mg、0.774ミリモル)、HATU(294mg、0.774ミリモル)及びジイソプロピルエチルアミン(0.27mL、1.548ミリモル)を順次加え、室温で5時間攪拌した。反応液に酢酸エチルを加え、蒸留水及び飽和食塩水にて洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(194mg、100%)を得た。
(2)3-ヒドロキシ-N-(4-イソプロポキシフェニル)シクロヘキサンカルボキサミドの合成
上記(1)で合成した化合物(175mg、0.636ミリモル)のメタノール(6mL)溶液に水素化ホウ素ナトリウム(28.9mg、0.763ミリモル)を氷冷下加え、しばらく攪拌後、室温でさらに3時間攪拌した。飽和塩化アンモニウム水溶液を加え、しばらく攪拌後、反応溶媒を減圧濃縮した。得られた残渣に蒸留水を加え、クロロホルムにて2度抽出した。有機層を集め、硫酸マグネシウムにて乾燥後、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(162mg、92%)を得た。
(3)表題化合物の合成
上記(2)で得られた化合物(162mg、0.584ミリモル)のクロロホルム(5mL)溶液中にトリエチルアミン(0.098mL、0.7ミリモル)及びメタンスルホニルクロリド(0.05mL、0.642ミリモル)を室温で順次加え、24時間攪拌した。反応溶液を蒸留水で1度洗浄後、硫酸マグネシウムにて乾燥し、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、表題化合物(179mg、86%)をシス体とトランス体の混合物として得た。
3-{[(5-イソプロポキシピリジン-2-イル)アミノ]カルボニル}シクロヘキシルメタンスルホネート
6-ブロモピリジン-3-オール(1g、5.75ミリモル)のDMF(10mL)溶液に2-ブロモプロパン(1.13mL、12ミリモル)及び炭酸カリウム(1.43g、10.4ミリモル)を順次加え、80度で2時間攪拌した。溶液の温度を室温に戻し、酢酸エチルにて希釈後、蒸留水にて2度、飽和食塩水にて1度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮して、目的物(1.28g、100%)を得た。
(2)エチル5-イソプロポキシピリジン-2-カルボン酸の合成
上記(1)で得た化合物(600mg、2.78ミリモル)のエタノール(6mL)とDMF(3mL)との混合溶液中に酢酸パラジウム(31.2mg、0.14ミリモル)及び1,1’-ビス(ジフェニルホスフィノ)フェロセン(77.1mg、0.14ミリモル)を加え、一酸化炭素存在下、50度で22時間攪拌した。反応溶液を酢酸エチルにて希釈後、飽和重炭酸ナトリウム水溶液にて2度、飽和食塩水にて1度洗浄した。得られた有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(386mg、66%)を得た。
(3)5-イソプロポキシピリジン-2-カルボン酸の合成
上記(2)で得られた化合物(386mg、1.84ミリモル)のエタノール(3mL)溶液に5規定水酸化ナトリウム水溶液(1.8mL)を加え、50度で3時間攪拌した。反応液を氷冷し、5規定塩酸水溶液にて中和し、反応液をクロロホルムにて抽出した。有機層を集め、硫酸マグネシウムにて乾燥させ、減圧濃縮し、目的物(258mg、78%)を得た。
(4)tert-ブチル(5-イソプロポキシピリジン-2-イル)カーバメートの合成
上記(3)で得られた化合物(255mg、1.4ミリモル)のtert-ブタノール(5mL)溶液にトリエチルアミン(0.585mL、4.2ミリモル)及びジフェニルリン酸アジド(0.453mL、2.1ミリモル)を順次加え、100度にて5時間攪拌した。反応液を室温に戻し、減圧濃縮した。残渣を酢酸エチルに溶解させ、1規定水酸化ナトリウム水溶液にて2度、飽和食塩水にて1度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(137mg、39%)を得た。
(5)2-アミノ-5-イソプロポキシピリジン塩酸塩の合成
上記(4)で得られた化合物(137mg、0.54ミリモル)のクロロホルム(5mL)溶液に4規定塩酸-酢酸エチル溶液(4.5mL)を加え、室温にて18時間攪拌した。反応溶液を減圧濃縮し、目的物(102mg、100%)を得た。
(6)表題化合物の合成
上記(5)で得られた化合物を原料として参考例1に準じた方法により、表題化合物を得た。
(1R*,3R*)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボン酸
文献(Tetrahedron、2003年,59巻、7465-7471頁)公知の化合物であるメチル(1S*,3R*)-3-ヒドロキシシクロヘキサンカルボン酸(857mg、5.42ミリモル)の酢酸エチル(10mL)溶液に、氷冷下、トリエチルアミン(1.51mL、10.84ミリモル)及び塩化メシル(0.634mL、8.13ミリモル)を順次加え、その後室温にて1時間攪拌した。反応溶液を氷冷下しばらく静置し、反応液をろ過した。得られたろ液を減圧濃縮し、目的物(1.18g、92%)を得た。
(2)メチル(1R*,3R*)-3-(ピリジン-2-イルチオ)シクロヘキサンカルボン酸の合成
上記(1)で合成した化合物(300mg、1.27ミリモル)のDMF(5mL)溶液中に2-メルカプトピリジン(847mg、7.62ミリモル)と炭酸セシウム(2.48g、7.62ミリモル)を順次加え、80度にて4時間攪拌した。反応溶液を室温に戻し、酢酸エチルにて希釈し、蒸留水にて2度、飽和食塩水にて1度洗浄した。有機層を硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(252mg、79%)を得た。
(3)メチル(1R*,3R*)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボン酸の合成
上記(2)で合成した化合物(250mg、0.995ミリモル)のクロロホルム(5mL)溶液にm-クロロ過安息香酸(622mg(69%含有)、2.49ミリモル)を加え、室温にて24時間攪拌した。飽和チオ硫酸ナトリウム水溶液を加え、しばらく攪拌後、クロロホルムにて2度抽出した。有機層を集め、硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、目的物(240mg、85%)を得た。
(4)表題化合物の合成
上記(3)で合成した化合物(240mg、0.847ミリモル)のメタノール(5mL)溶液に5規定水酸化ナトリウム水溶液(0.847mL)を加え、室温で14時間攪拌した。反応溶液を氷冷後、5規定塩酸水溶液にて中和した。クロロホルムにて3度抽出した。有機層を集め、硫酸マグネシウムにて乾燥後、減圧濃縮し、表題化合物(210mg、92%)を得た。
Claims (13)
- 式(I)
Zは、下記の式(II-1)、(II-2)及び(II-3)からなる群から選択され、
Yは、CR3又はNを表し、但しYが、Nを表す場合、(II-2)又は(II-3)においてnは、0又は2を表し、
R1は、C1-6アルキル、C3-8シクロアルキル、アリール又はヘテロアリールを表し、該アルキル、シクロアルキル、アリール又はヘテロアリールは、ヒドロキシ、シアノ、カルボキシル、スルホ、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C3-8シクロアルキル、C1-6アルコキシ、ハロC1-6アルコキシ、アミノ(該アミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、カルバモイル(該カルバモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、スルファニル(該スルファニルは、C1-6アルキル、アリール若しくはヘテロアリールで1置換されていてもよい)、C1-6アルキルスルフィニル、アリールスルフィニル、ヘテロアリールスルフィニル、C1-6アルキルスルホニル、アリールスルホニル、ヘテロアリールスルホニル、スルファモイル(該スルファモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルキルスルホニルアミノ、アリールスルホニルアミノ、ヘテロアリールスルホニルアミノ、C1-6アルキルカルボニル、アリールカルボニル、ヘテロアリールカルボニル、C1-6アルコキシカルボニル、アリールオキシカルボニル、ヘテロアリールオキシカルボニル、カルバモイルアミノ(該カルバモイルアミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルコキシカルボニルアミノ、アリールオキシカルボニルアミノ、ヘテロアリールオキシカルボニルアミノ、C1-6アルキルカルボニルアミノ、アリールカルボニルアミノ、ヘテロアリールカルボニルアミノ、アリール、ヘテロアリール、アラルキル、ヘテロアラルキル、アラルキルオキシ及びヘテロアラルキルオキシからなる群から選択される置換基で置換されていてもよく、
R2は、フェニル又はヘテロアリールを表し、該フェニル又はヘテロアリールは、ヒドロキシ、シアノ、カルボキシル、スルホ、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C3-8シクロアルキル、C1-6アルコキシ、ハロC1-6アルコキシ、アミノ(該アミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、カルバモイル(該カルバモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、スルファニル(該スルファニルは、C1-6アルキル、アリール若しくはヘテロアリールで1置換されていてもよい)、C1-6アルキルスルフィニル、アリールスルフィニル、ヘテロアリールスルフィニル、C1-6アルキルスルホニル、アリールスルホニル、ヘテロアリールスルホニル、スルファモイル(該スルファモイルは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルキルスルホニルアミノ、アリールスルホニルアミノ、ヘテロアリールスルホニルアミノ、C1-6アルキルカルボニル、アリールカルボニル、ヘテロアリールカルボニル、C1-6アルコキシカルボニル、アリールオキシカルボニル、ヘテロアリールオキシカルボニル、カルバモイルアミノ(該カルバモイルアミノは、C1-6アルキル、アリール若しくはヘテロアリールで1乃至2置換されていてもよい)、C1-6アルコキシカルボニルアミノ、アリールオキシカルボニルアミノ、ヘテロアリールオキシカルボニルアミノ、C1-6アルキルカルボニルアミノ、アリールカルボニルアミノ、ヘテロアリールカルボニルアミノ、アリール、ヘテロアリール、アラルキル、ヘテロアラルキル、アラルキルオキシ及びヘテロアラルキルオキシからなる群から選択される置換基で置換されていてもよく、
R3及びR4は、それぞれ独立して、水素原子、C1-6アルキル、C3-8シクロアルキル、アラルキル、ヘテロアラルキル、アリール又はヘテロアリールを表し、該アルキル、シクロアルキル、アラルキル、ヘテロアラルキル、アリール又はヘテロアリールは、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C1-6アルコキシ及びハロC1-6アルコキシからなる群から選択される置換基で置換されていてもよく、
M1、M2、M3及びM4は、それぞれ独立して、水素原子若しくはハロゲンで置換されていてもよいC1-6アルキルを表すか、或いはM1が、M2、M3又はM4と一緒になって、-CH2-若しくは-CH2-CH2-を形成するか、又はM4が、M2と一緒になって、-CH2-若しくは-CH2-CH2-を形成する]で表される化合物又は薬学的に許容されるその塩。 - R1が、C1-6アルキル、C3-8シクロアルキル、アリール又はヘテロアリールを表し、該アルキル、シクロアルキル、アリール又はヘテロアリールは、ハロゲン、C1-6アルキル、ハロC1-6アルキル及びC1-6アルコキシからなる群から選択される置換基で置換されていてもよい、請求項1に記載の化合物又は薬学的に許容されるその塩。
- R1が、メチル、エチル、プロピル、ブチル、シクロプロピル、フェニル、2-ピリジル、3-ピリジル、4-ピリジル、2-メトキシフェニル、ピリミジン-2-イル、3-メトキシフェニル、4-メトキシフェニル、2-フルオロフェニル、3-フルオロフェニル、4-フルオロフェニル、2-クロロフェニル、3-フルオロフェニル、4-フルオロフェニル、2-クロロフェニル、3-クロロフェニル、4-クロロフェニル、1-メチル-1H-イミダゾール-4-イル、1H-イミダゾール-4-イル、5-メチル-1,3,4-チアジアゾール-2-イル又は1,3,4-チアジアゾール-2-イルである請求項1に記載の化合物又は薬学的に許容されるその塩。
- R2が、フェニル又はヘテロアリールを表し、該フェニル又はヘテロアリールは、ハロゲン、C1-6アルキル、ハロC1-6アルキル、C1-6アルコキシ、C3-6シクロアルキル、アリール、アラルキル及びアラルキルオキシからなる群から選択される置換基で置換されていてもよい、請求項1~3のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩。
- R2が、フェニル、2-フルオロフェニル、3-フルオロフェニル、4-フルオロフェニル、2-クロロフェニル、3-クロロフェニル、4-クロロフェニル、2-メトキシフェニル、3-メトキシフェニル、4-メトキシフェニル、2-メチルフェニル、3-メチルフェニル、4-メチルフェニル、2-イソプロピルフェニル、3-イソプロピルフェニル、4-イソプロピルフェニル、2-イソプロポキシフェニル、3-イソプロポキシフェニル、4-イソプロポキシフェニル、2-ベンジルフェニル、3-ベンジルフェニル、4-ベンジルフェニル、2-ベンジロキシフェニル、3-ベンジロキシフェニル、4-ベンジロキシフェニル、5-イソプロポキシフェニルピリジン-2-イル、6-イソプロポキシフェニルピリジン-3-イル、5-イソプロポキシピリミジン-2-イル、3-メトキシピリジン-2-イル、3-シクロプロピル-1H-ピラゾール-5-イル又は5-イソプロポキシ-1H-ピラゾール-3-イルである請求項1~3のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩。
- Zが、式(II-1)で表され、mが0又は1である、請求項1~5のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩。
- Zが、式(II-2)で表される、請求項1~5のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩。
- YがCR3であり、R3が水素原子、メチル、エチル、プロピル、イソプロピル、フェニル、ピリジン-2-イル、ピリジン-3-イル、ピリジン-4-イル又はベンジルである、請求項1~7のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩。
- M1、M2、M3及びM4が、いずれも水素原子である、請求項1~8のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩。
- 式(I)で表される化合物が、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(フェニルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(ピリミジン-2-イルスルホニル)シクロヘキサンカルボキサミド、
(1R*,3R*)-N-(5-イソプロポキシピリジン-2-イル)-3-(1,3-チアゾール-2-イルスルホニル)シクロヘキサンカルボキサミド、及び
(1R*,3R*)-N-(3-イソプロポキシ-1H-ピラゾール-5-イル)-3-(ピリジン-2-イルスルホニル)シクロヘキサンカルボキサミドからなる群から選択される、請求項1に記載の化合物又は薬学的に許容されるその塩。 - 請求項1~10のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩を有効成分とする長鎖脂肪酸伸長酵素(LCE)阻害剤。
- 請求項1~10のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩を含有する医薬組成物。
- 請求項1~10のいずれかの請求項に記載の化合物又は薬学的に許容されるその塩を有効成分とする、糖尿病、肥満症又は非アルコール性脂肪肝の予防剤又は治療剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009547047A JP5377329B2 (ja) | 2007-12-26 | 2008-12-16 | スルホニル置換六員環誘導体 |
AU2008341953A AU2008341953B2 (en) | 2007-12-26 | 2008-12-16 | Sulfonyl substituted 6-membered ring derivative |
CA2707447A CA2707447C (en) | 2007-12-26 | 2008-12-16 | Sulfonyl-substituted 6-membered ring derivative |
US12/745,761 US8124807B2 (en) | 2007-12-26 | 2008-12-16 | Sulfonyl-substituted 6-membered ring derivative |
EP08864487.7A EP2236494B1 (en) | 2007-12-26 | 2008-12-16 | Sulfonyl substituted 6-membered ring derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-334073 | 2007-12-26 | ||
JP2007334073 | 2007-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009081789A1 true WO2009081789A1 (ja) | 2009-07-02 |
Family
ID=40801094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/072811 WO2009081789A1 (ja) | 2007-12-26 | 2008-12-16 | スルホニル置換六員環誘導体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8124807B2 (ja) |
EP (1) | EP2236494B1 (ja) |
JP (1) | JP5377329B2 (ja) |
AU (1) | AU2008341953B2 (ja) |
CA (1) | CA2707447C (ja) |
WO (1) | WO2009081789A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011102514A1 (ja) * | 2010-02-22 | 2011-08-25 | 武田薬品工業株式会社 | 芳香環化合物 |
US8163898B2 (en) | 2007-09-21 | 2012-04-24 | Msd K. K. | 4-sulfonylpiperidine derivatives |
US8314094B2 (en) | 2007-10-05 | 2012-11-20 | Msd K.K | Benzoxazinone derivative |
WO2013187462A1 (ja) | 2012-06-14 | 2013-12-19 | 第一三共株式会社 | ピペリジニルピラゾロピリジン誘導体 |
WO2015087994A1 (ja) | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | 5-ヒドロキシ-4-(トリフルオロメチル)ピラゾロピリジン誘導体 |
WO2016043189A1 (ja) * | 2014-09-16 | 2016-03-24 | 塩野義製薬株式会社 | トリフェニルブテン誘導体の製造方法 |
US10472312B2 (en) | 2016-03-15 | 2019-11-12 | Shionogi & Co., Ltd. | Method for producing phenoxyethanol derivative |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039407A1 (en) | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
JP2005501120A (ja) * | 2001-08-21 | 2005-01-13 | メルク シャープ エンド ドーム リミテッド | 新規のシクロヘキシルスルホン |
WO2005005665A1 (ja) | 2003-07-11 | 2005-01-20 | Banyu Pharmaceutical Co., Ltd. | Lceによる肥満治療に有効な化合物の評価方法 |
WO2006131713A1 (en) * | 2005-06-06 | 2006-12-14 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
WO2007058942A2 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0607756A2 (pt) * | 2005-02-18 | 2010-05-18 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos |
WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
CA2699275C (en) | 2007-09-21 | 2015-08-25 | Banyu Pharmaceutical Co., Ltd. | 4-sulfonylpiperidine derivative |
AU2008308092B2 (en) | 2007-10-05 | 2013-07-11 | Msd K.K. | Benzoxazinone derivative |
WO2009099086A1 (ja) | 2008-02-06 | 2009-08-13 | Banyu Pharmaceutical Co., Ltd. | 3位置換スルホニルピペリジン誘導体 |
-
2008
- 2008-12-16 CA CA2707447A patent/CA2707447C/en active Active
- 2008-12-16 AU AU2008341953A patent/AU2008341953B2/en active Active
- 2008-12-16 EP EP08864487.7A patent/EP2236494B1/en active Active
- 2008-12-16 US US12/745,761 patent/US8124807B2/en active Active
- 2008-12-16 WO PCT/JP2008/072811 patent/WO2009081789A1/ja active Application Filing
- 2008-12-16 JP JP2009547047A patent/JP5377329B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039407A1 (en) | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
JP2005501120A (ja) * | 2001-08-21 | 2005-01-13 | メルク シャープ エンド ドーム リミテッド | 新規のシクロヘキシルスルホン |
WO2005005665A1 (ja) | 2003-07-11 | 2005-01-20 | Banyu Pharmaceutical Co., Ltd. | Lceによる肥満治療に有効な化合物の評価方法 |
WO2006131713A1 (en) * | 2005-06-06 | 2006-12-14 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
WO2007058942A2 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
Non-Patent Citations (7)
Title |
---|
CELL, vol. 126, 2006, pages 691 - 699 |
HARVEY, I. W. ET AL.: "Radical induced cyclizations of unsaturated allylic sulfones containing an activating electron withdrawing group", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999), 1993, pages 191 - 196 * |
J. BIOL. CHEM., vol. 276, 2001, pages 45358 - 45366 |
J. LIPID RES., vol. 43, no. 6, 2002, pages 911 - 920 |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 48, 2001, pages 45358 - 45366 |
LEE S. H. ET AL., CELL, vol. 126, 2006, pages 691 - 699 |
MATSUZAKA T. ET AL., J. LIPID RES., vol. 43, no. 6, 2002, pages 911 - 920 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8163898B2 (en) | 2007-09-21 | 2012-04-24 | Msd K. K. | 4-sulfonylpiperidine derivatives |
US8314094B2 (en) | 2007-10-05 | 2012-11-20 | Msd K.K | Benzoxazinone derivative |
WO2011102514A1 (ja) * | 2010-02-22 | 2011-08-25 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013187462A1 (ja) | 2012-06-14 | 2013-12-19 | 第一三共株式会社 | ピペリジニルピラゾロピリジン誘導体 |
WO2015087994A1 (ja) | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | 5-ヒドロキシ-4-(トリフルオロメチル)ピラゾロピリジン誘導体 |
WO2016043189A1 (ja) * | 2014-09-16 | 2016-03-24 | 塩野義製薬株式会社 | トリフェニルブテン誘導体の製造方法 |
US10472312B2 (en) | 2016-03-15 | 2019-11-12 | Shionogi & Co., Ltd. | Method for producing phenoxyethanol derivative |
Also Published As
Publication number | Publication date |
---|---|
JP5377329B2 (ja) | 2013-12-25 |
CA2707447C (en) | 2016-03-08 |
US20100249147A1 (en) | 2010-09-30 |
JPWO2009081789A1 (ja) | 2011-05-06 |
US8124807B2 (en) | 2012-02-28 |
EP2236494A1 (en) | 2010-10-06 |
EP2236494B1 (en) | 2016-08-31 |
AU2008341953B2 (en) | 2013-05-02 |
CA2707447A1 (en) | 2009-07-02 |
EP2236494A4 (en) | 2013-08-07 |
AU2008341953A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5501226B2 (ja) | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 | |
JP5377329B2 (ja) | スルホニル置換六員環誘導体 | |
TWI422579B (zh) | 新化合物 | |
JP5537159B2 (ja) | 3位置換スルホニルピペリジン誘導体 | |
JP5319536B2 (ja) | 4−スルホニルピペリジン誘導体 | |
EP2801573A1 (en) | Hydantoine derivatives as CD38 inhibitors | |
JPWO2009041475A1 (ja) | ピラゾール−3−イル−ベンズアミド誘導体の製造方法 | |
US9242978B2 (en) | Phenylacetamide compound and pharmaceutical containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08864487 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008341953 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2707447 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12745761 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008341953 Country of ref document: AU Date of ref document: 20081216 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2009547047 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2008864487 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008864487 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |